The CDK inhibitor abemaciclib (Verzenio) has been added to the PBS from 1 January as a treatment for advanced HR+/HER2- breast cancer in non-premenopausal patients. The treatment, adds to ribociclib (Kisqali) and palbociclib (Ibrance) as PBS listed CDK inhibitors for first line treatment, is not associated with QT interval prolongation and therefore “provides a CDK ...
Abemaciclib listed on the PBS for breast cancer
By Mardi Chapman
21 Jan 2020